A Phase 2 interventional study of SHR-1905 Injection and SHR-1905 Injection Blank Preparation in Moderate-to-severe Atopic Dermatitis, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-08.
Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd. — 3 open to participants now, 5 under way, 2 of them phase 3. Dermatitis, Atopic · Jiangsu HengRui Medicine Co., Ltd..
Among the 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd., this one is the 11th largest by planned enrollment, is one of 2 that started in 2025, is one of 6 in phase 2, and was the 10th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →3 of the 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:
Guangdong Hengrui Pharmaceutical Co., Ltd · Sites in China
Ages 12–17
Chengdu Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 4
First in 2019; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is close to the median of 82 across 1,246 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 159 across the 14 interventional studies. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Guangdong Hengrui Pharmaceutical Co., Ltd, one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Guangdong Hengrui Pharmaceutical Co., Ltd is the lead sponsor of 59 studies on the registry; 25 are open to participants now.
3 of the studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07309055Phase 3Guangdong Hengrui Pharmaceutical Co., LtdA Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis | 2027-11 |
| NCT07698756Chengdu Suncadia Medicine Co., Ltd.A Clinical Study of HRS-8797 in Healthy Participants | 2026-12 |
| NCT07321951Guangdong Hengrui Pharmaceutical Co., LtdA Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial was designed to evaluate the efficacy and safety of SHR-1905 in patients with moderate-to-severe atopic dermatitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose 1.
Drug: SHR-1905 Injection
Drug: SHR-1905 Injection Blank Preparation
Dose 2.
Drug: SHR-1905 Injection
SHR-1905 injection.
SHR-1905 injection blank preparation.
The proportion of subjects whose Eczema Area and Severity Index (EASI) score decreased ≥ 75% compared to the baseline.
Eczema Area and Severity Index (EASI) score using the Eczema Area and Severity Index scale.
Time frame: Week 16.
The proportion of subjects with Investigator's Global Assessment (IGA) score of 0 or 1 (on a 0-4 scale) and a decrease of ≥2 points from the baseline.
Investigator's Global Assessment (IGA) score using the Investigator Global Assessment (IGA) scale.
Time frame: At Day14、Day28、Day56、Day84、Day112、Day140、Day168、Day210、Day252.
The proportion of subjects whose Investigator's Global Assessment (IGA) score decreased ≥ 2 points compared to the baseline.
Investigator's Global Assessment (IGA) score using the Investigator Global Assessment (IGA) scale.
Time frame: At Day14、Day28、Day56、Day84、Day112、Day140、Day168、Day210、Day252.
The change value of change in the Itch Numeric Rating Scale (Itch-NRS) score from the baseline.
The Itch Numeric Rating Scale (Itch-NRS) score using the the Worst Itch Numeric Rating Scale.
Time frame: At Day14、Day28、Day56、Day84、Day112、Day140、Day168、Day210、Day252.
The percentage of change in the Itch Numeric Rating Scale (Itch-NRS) score from the baseline.
The Itch Numeric Rating Scale (Itch-NRS) score using the the Worst Itch Numeric Rating Scale.
Time frame: At Day14、Day28、Day56、Day84、Day112、Day140、Day168、Day210、Day252.
The proportion of subjects whose EASI score decreased ≥ 75% compared to the baseline.
EASI score using the EASI scale.
Time frame: At Day14、Day28、Day56、Day84、Day112、Day140、Day168、Day210、Day252.
The proportion of subjects whose EASI score decreased ≥ 90% compared to the baseline.
EASI score using the EASI scale.
Time frame: At Day14、Day28、Day56、Day84、Day112、Day140、Day168、Day210、Day252.
The proportion of subjects whose EASI score decreased ≥ 50% compared to the baseline.
EASI score using the EASI scale.
Time frame: At Day14、Day28、Day56、Day84、Day112、Day140、Day168、Day210、Day252.
The change value in EASI score from the baseline.
EASI score using the EASI scale.
Time frame: At Day14、Day28、Day56、Day84、Day112、Day140、Day168、Day210、Day252.
The percentage of change in EASI score from the baseline.
EASI score using the EASI scale.
Time frame: At Day14、Day28、Day56、Day84、Day112、Day140、Day168、Day210、Day252.
The change in Body Surface Area Involvement of Atopic Dermatitis (BSA) from the baseline.
BSA score using the BSA scale.
Time frame: At Day14、Day28、Day56、Day84、Day112、Day140、Day168、Day210、Day252.
The percentage of change in Body Surface Area Involvement of Atopic Dermatitis (BSA) from the baseline.
BSA score using the BSA scale.
Time frame: At Day14、Day28、Day56、Day84、Day112、Day140、Day168、Day210、Day252.
Adverse events (AEs).
Time frame: At Day14、Day28、Day56、Day84、Day112、Day140、Day168、Day210、Day252.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Sep 2026, 10 months after the start.
Of 195 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 10 months is below that.
Counting every sponsor, half of 223 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SHR-1905
Guangdong Hengrui Pharmaceutical Co., Ltd →